Search Within

Gynecology Disease Management Team

Formats
  1. Journal Article (2473)
  2. Meeting Abstract (2112)
  3. Book Section (226)
  4. Review (135)
  5. Editorial (88)
  6. Guidelines (39)
  7. Correspondence (19)
  8. Conference Paper (16)
  9. Miscellaneous (13)
  10. Research Letter (12)
  11. Book Whole (11)
Groups
  1. Surgery (2362)
  2. Department of Medicine (2268)
  3. Solid Tumor Oncology Division (2217)
  4. GDMT, Surgery (1974)
  5. GDMT, Medicine (1910)
  6. Gynecologic Medicine Service (1877)

More Groups

People
  1. Nadeem Abu-Rustum (902)
  2. Robert Soslow (797)
  3. Dennis Chi (716)
  4. Britta Weigelt (646)
  5. Carol Aghajanian (615)
  6. Mario Leitao (582)

More People

Years
  1. 2025 (161)
  2. 2024 (308)
  3. 2023 (332)
  4. 2022 (361)
  5. 2021 (308)
  6. 2020 (356)

More Years

Publications
  1. Gynecologic Oncology (950)
  2. Journal of Clinical Oncology (543)
  3. Modern Pathology (354)
  4. International Journal of Gynecological Cancer (321)
  5. Laboratory Investigation (311)
  6. International Journal of Radiation Oncology, Biology, Physics (223)

More Publications

Publishers
  1. Elsevier B.V. (1001)
  2. American Society of Clinical Oncology (598)
  3. Lippincott Williams & Wilkins (584)
  4. Elsevier Inc. (481)
  5. Nature Publishing Group (424)
  6. Nature Research (356)

More Publishers

Results (5144)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Digital technical and informal resources of breast cancer patients from 2012 to 2020: Questionnaire-based longitudinal trend study
    Journal Article

    Mallmann, C. A.; Domröse, C. M.; Schröder, L.; Engelhardt, D.; Bach, F.; Rueckel, H.; Abramian, A.; Kaiser, C.; Mustea, A.; Faridi, A.; more...
    JMIR Cancer (2021)

    Fulltext@MSK | Save
  • SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer
    Meeting Abstract

    Vergote, I.; Perez-Fidalgo, J. A.; Hamilton, E. P.; Van Gorp, T.; Valabrega, G.; Laenen, A.; Oza, A. M.; Levy, T.; Cibula, D.; Sehouli, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC)
    Meeting Abstract

    Kwan, T.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A. P.; Colombo, N.; Weberpals, J. I.; Clamp, A. R.; Scambia, G.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC)
    Meeting Abstract

    Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors - Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort
    Meeting Abstract

    Hamilton, E. P.; Jackson, C. C.; Eskander, R. N.; Backes, F. J.; Makker, V.; Musa, F.; Olawaiye, A.; Alldredge, J.; Pothuri, B.; Secord, A. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Banerjee, S. N.; Monk, B. J.; Van Nieuwenhuysen, E.; Moore, K. N.; Oaknin, A.; Fabbro, M.; Colombo, N.; O'Malley, D. M.; Coleman, R. L.; Pachter, J. A.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study
    Meeting Abstract

    Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Liu, Y. L.; Provencher, D. M.; McCormick, C.; ElNaggar, A.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors
    Meeting Abstract

    Meric-Bernstam, F.; Hainsworth, J.; Bose, R.; Burris, H. A. 3rd; Friedman, C. F.; Kurzrock, R.; Swanton, C.; Wang, Y.; Levy, J.; Schulze, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial
    Meeting Abstract

    Balar, A. V.; Milowsky, M. I.; O'Donnell, P. H.; Alva, A. S.; Kollmeier, M.; Rose, T. L.; Pitroda, S.; Kaffenberger, S. D.; Rosenberg, J. E.; Francese, K.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save